Epidural catheter placement in the patient with pain and palliative care: Narrative Review
##plugins.themes.bootstrap3.article.details##
10% of patients with cancer pain who are on optimal pharmacological systemic therapy have inadequate control, explained by treatment refractoriness or intolerable adverse effects. Although interventional techniques are considered as the fourth step of the pain management ladder proposed by the World Health Organization, in cancer patients, the anticipated application of these interventional methods (such as neuroaxial analgesia and nerve blocks) can represent advantages. It is suggested a multidisciplinary approach that includes several clinical services to generate the greatest impact of this type of techniques in the treatment of cancer pain, taking into account its indications and contraindications. The analgesia via the neuroaxial route, directly directed to the spinal cord pain transmission routes, provides better control of pain, allows the reduction of analgesic doses and improves the quality of life of the patients. The choice between drug delivery systems, either implantable and external pumps depends mainly on the life expectancy of the patient
pain, chronic pain, pain management, analgesia, neoplasmdolor, dolor crónico, manejo, analgesia, neoplasia
2. Smyth CE, Jarvis V, Poulin P. Brief review: Neuraxial analgesia in refractory malignant pain. Can J Anesth. 2014;61(2):141-53.
3. Jost L, Roila F. Management of cancer pain: ESMO Clinical Practice Guidelines. Ann Oncol. 2010;21 Suppl 5:v257-60.
4. Vargas-Schaffer G. Is the WHO analgesic ladder still valid?: Twenty-four years of experience. Can Fam Physician. 2010;56(6):514-7.
5. Jeon YS, Lee JA, Choi JW, Kang EG, Jung HS, Kim HK, et al. Efficacy of epidural analgesia in patients with cancer pain: a retrospective observational study. Yonsei Med J. 2012;53(3):649-53.
6. Mella S M, Zamora P, Mella L M, Alfaro J, Uceda P. Niveles de evidencia clínica y grados de recomendación. Rev Soc Andaluza Trauma y Ortop. 2012;29(1-2):59-72.
7. Brown DL, Wedel DJ, Miller RD. Anestesia intradural, epidural y caudal. En: Miller RD, editor. Anestesia. Barcelona: Doyma; 1993. p. 1269-74.
8. Paul G, Bruce F, Robert K, Bernards CM. Chapter 25: Epidural and spinal anesthesia. Clinical Anesthesia. 2006. 1-86 p.
9. Teoh DA, Santosham KL, Lydell CC, Smith DF, Beriault MT. Surface anatomy as a guide to vertebral level for thoracic epidural placement. Anesth Analg. 2009;108(5):1705-7.
10. Reynolds F. Damage to the conus medullaris following spinal anaesthesia. Anaesthesia. 2001 Mar;56(3):238-47.
11. Manoj K, Vandepitte C. Introduction to ultrasound guided neuraxial and perineuraxial techniques. NYSORA [Internet]. 2013. Disponible en: http://www.nysora.com/techniques/neuraxial-and-perineuraxial-techniques/ultrasound-guided/3275-introduction.html
12. Tran DQH, González AP, Bernucci F, Finlayson RJ. Confirmation of loss-of-resistance for epidural analgesia. Reg Anesth Pain Med. 2015;40(2):166-73.
13. Stearns L, Boortz-Marx R, Du Pen S, Friehs G, Gordon M, Halyard M, et al. Intrathecal drug delivery for the management of cancer pain: a multidisciplinary consensus of best clinical practices. J Support Oncol. 2005;3(6):399-408.
14. Ruppen W, Derry S, McQuay HJ, Moore RA. Infection rates associated with epidural indwelling catheters for seven days or longer: systematic review and meta-analysis. BMC Palliat Care. 2007;6:3.
15. Mercadante S, Porzio G, Gebbia V. Spinal analgesia for advanced cancer patients: An update. Crit Rev Oncol/Hematol. 2011;82:227-32.
16. Chai T, Bruel BM, Nouri KH, Driver L. Complications after intrathecal drug delivery due to the underlying malignancy in two patients with intractable cancer pain. Pain Physician. 2013;16(2):E107-11.